Durvalumab for patients who had mild radiation pneumonitis after concurrentchemoradiotherapy.

Durvalumab for patients who had mild radiation pneumonitis after concurrentchemoradiotherapy. - Durvalumab in patients who had radiation pneumonitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036061

Enrollment

Registered

2019-03-01

Start date

2019-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stage III NSCLC patients who had response of CCRT Patients who had grade 1 pneumonitis within 42 days after CCRT Patients who started durvalumab within 42 days after CCRT PS0-1

Exclusion criteria

Exclusion criteria: Patients who do not meet the criteria above

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
Progression free survival	—

Countries

Asia(except Japan)

Contacts

Public ContactDaichi Fujimoto

Kobe city medical center general hospotal Division of respiratory medicine

daichi@kcho.jp078-302-4321

Outcome results